Janssen at CROI: Harnessing Innovation in HIV Therapeutics
Janssen at CROI: Harnessing Innovation in HIV Therapeutics
HIV remains one the biggest public health threats of our time. It is estimated that 36.7 million people are currently living with HIV globally, with at least 1.8 million more becoming newly infected each year.1
We know that defeating HIV is an ambitious goal that requires multiple approaches and innovative science. While significant progress has been made, there is still much more to be done to develop holistic, sustainable, and measurable solutions that deliver long-term impact.
Over the last 10 years, Janssen has brought many new therapies to market with the aim to serve patients at all stages of diagnosis and treatment. These therapies have helped to transform the efficacy and tolerability of treatment and helped millions of patients around the world live healthier lives.
We are proud of what has been achieved, and we will not stop here. At Janssen, we will continue to leverage our knowledge, science and expertise and partner with others to do more for people living with HIV.
Therefore, with the aim to make HIV history, we are innovating across the whole continuum of HIV care. Research that we are unveiling at the upcoming Conference on Retroviruses and Opportunistic Infections (CROI) is demonstrating just that. This data will showcase improvements in the delivery of treatment to people living with HIV – both for those newly diagnosed and for patients who have been on treatment for many years.
Our aim for the treatment of HIV is to provide long-term remission from the infection, and one day in the future strive for full viral eradication. To achieve this, we are partnering with others and exploring novel strategies like therapeutic vaccines, long-acting regimens and immune-based therapies, which may be a potential way forward in ending the need for people living with HIV to take life-long therapy.
We’re proud of the progress we’re making in treating HIV as we seek to improve outcomes for those living with the condition or at greatest risk of contracting the virus, and we’re thrilled to have the opportunity to share our research with the international community at CROI.
With no time to waste, we are working every day to reduce HIV-related morbidity and mortality and help patients live long, healthy and productive lives.
Brian Woodfall completed his medical degree at the University of Saskatchewan, Canada followed by post-graduate training at the University of British Columbia. For 15 years he had a private practice with a focus on HIV disease. During this time he was involved in teaching, research and community-based volunteer organizations. As a co-founder of Spectrum Health Care Ltd. in Vancouver, BC, he was instrumental in the conception, funding, implementation and day-to-day management of an integrated multi-disciplinary clinic dealing with HIV disease. In 2003, Brian joined the pharmaceutical industry at Tibotec, a Johnson & Johnson company specializing in the discovery and development of innovative HIV/AIDS drugs and superior anti-infectives for diseases of high unmet medical need. As head of the Medical Department at Tibotec, he had responsibilities across global development in the areas of HIV, hepatitis C and tuberculosis. From 2011 to 2013, Brian held the role of Vice President for Medical Affairs for Janssen covering the EMEA region (Europe, Middle East and Africa). Brian is currently Head of Development for Infectious Diseases at Janssen.